Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

The best Amazon Big Spring Sale deals you can still get

April 1, 2026

2 charged in highway shooting that killed Alberta man in ‘senseless crime’

April 1, 2026

HII’s Ingalls Shipbuilding Launches Guided Missile Destroyer George M. Neal (DDG 131)

April 1, 2026

These Raspberry Pi price hikes are no joke

April 1, 2026

Yuki Brings Real-Time Cost Optimization to BigQuery

April 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Global Osteoarthritis Therapeutics Market Analysis Report 2024-2030, by Drug (NSAIDs, Corticosteroids), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), Sales Channel, End-use and Segment Forecasts
Press Release

Global Osteoarthritis Therapeutics Market Analysis Report 2024-2030, by Drug (NSAIDs, Corticosteroids), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), Sales Channel, End-use and Segment Forecasts

By News RoomApril 10, 20246 Mins Read
Global Osteoarthritis Therapeutics Market Analysis Report 2024-2030, by Drug (NSAIDs, Corticosteroids), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), Sales Channel, End-use and Segment Forecasts
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 10, 2024 (GLOBE NEWSWIRE) — The “Global Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, Drug (NSAIDs, Corticosteroids), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), Route of Administration, Sales Channel, End-use, Region, and Segment Forecasts, 2024-2030” report has been added to ResearchAndMarkets.com’s offering.

The global osteoarthritis therapeutics market size is estimated to reach USD 13.57 billion by 2030 and is projected to grow at a CAGR of 6.82% from 2024 to 2030. The osteoarthritis therapeutics market is on the rise, driven by an increase in OA cases, especially among the aging population. In the U.S. alone, there are over 32.5 million OA patients, highlighting the demand for effective treatments. Ongoing research and development efforts are focused on creating new therapies, with a particular emphasis on understanding the disease and developing solutions to address its challenges.

Managing OA proves difficult owing to its dense tissue structure, but the introduction of novel drugs such as intra-articular drug administration has accelerated the development of targeted drug delivery. Researchers are actively exploring disease-modifying drugs and bioadaptive carriers to enhance the development of innovative osteoarthritis treatments. Market players are taking initiatives to contribute to market expansion, as seen with OrthoTrophix, Inc. presenting clinical data and a registration plan for TPX-100 for knee osteoarthritis at BIO 2022.

In addition, significant efforts are being made by key pharmaceutical companies and research institutes in realm of research and development, especially for disease-modifying osteoarthritis drugs. For instance, BioSenic’s Phase 3 data presentation at the 2024 OARSI World Congress showcased the efficacy of JTA-004 in treating severe inflammatory knee osteoarthritis. The post hoc analysis concluded that JTA-004 is both safe and effective, offering targeted pain management for this specific subtype of condition. These advancements in targeted drug delivery and disease-modifying drugs, as demonstrated by presentations and positive trial results, are contributing to the expansion of the market for novel osteoarthritis treatments.

Moreover, the market for OA is experiencing significant growth owing to the introduction of personalized medications such as Bisphosphonates (anti-resorptive drugs) and Synvisc-ONE injection. In addition, pharmaceutical companies and research institutions are actively engaged in developing personalized treatments and cell-based therapies for OA. In December 2023, researchers at Columbia University made a breakthrough discovery of stem cells in adult mice capable of maintaining healthy cartilage in joints, with their decline contributing to OA development due to aging and injury.

Investing in this sector offers companies the opportunity to capitalize on evolving demands, thus gaining a competitive advantage. By leading innovative medication development, companies establish themselves as frontrunners, solidifying their position in the market. The advent of personalized OA medications and advancements in cell-based therapies are key drivers of market expansion, empowering companies to emerge as leaders in the field.

Osteoarthritis Therapeutics Market Report Highlights

  • Based on drug type, the viscosupplementation agents segment led the market with the largest revenue share of 36.63% in 2023, osteoarthritis therapeutics market due to their adoption and efficacy in managing OA symptoms
  • Based on anatomy, the knee osteoarthritis segment held a market with the largest revenue share of 41.96% in 2023. Knee osteoarthritis is one of the most common forms of chronic articular disease and osteoarthritis worldwide and is characterized by high disability & morbidity rates
  • Based on route of administration, the parenteral route segment held the market with the largest revenue share of 39.94% in 2023 and is expected to grow at a CAGR of 7.50% over the forecast period, due to its efficacy for certain therapies, better pharmacokinetics and pharmacodynamics, and ease of administration
  • Based on end-use, the hospital pharmacies segment held the market with the largest revenue share of 47.64% in 2023, owing to high hospitalization associated with OA

Key Attributes:

Report Attribute Details
No. of Pages 150
Forecast Period 2023 – 2030
Estimated Market Value (USD) in 2023 $8.59 Billion
Forecasted Market Value (USD) by 2030 $13.57 Billion
Compound Annual Growth Rate 6.8%
Regions Covered Global

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Osteoarthritis Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. High Prevalence of Osteoarthritis
3.2.1.2. Growing Aging Population
3.2.1.3. Technological Advancements
3.2.2. Market Restraint Analysis
3.2.2.1. Side Effects and adverse reactions
3.2.2.2. High cost of osteoarthritis therapeutics drugs
3.3. Osteoarthritis Therapeutics Market Analysis Tools

Chapter 4. Osteoarthritis Therapeutics Market: Drug Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Osteoarthritis Therapeutics Market by Drug Type Outlook
4.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
4.4. Viscosupplementation Agents
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Nonsteroidal Anti-inflammatory Drugs
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5.1.1. Naproxen
4.5.1.2. Aspirin
4.5.1.3. Diclofenac
4.5.1.4. Ibuprofen
4.5.1.5. Celecoxib
4.5.1.6. Meloxicam
4.5.1.7. Piroxicam
4.5.1.8. Ketoprofen
4.5.1.9. Other NSAIDs
4.5.2. Analgesics
4.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5.2.1.1. Duloxetine
4.5.2.1.2. Acetaminophen
4.5.3. Corticosteroids
4.5.4. Others

Chapter 5. Osteoarthritis Therapeutics Market: Anatomy Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Osteoarthritis Therapeutics Market Movement Analysis
5.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Anatomy, 2018 to 2030 (USD Million)
5.4. Knee Osteoarthritis
5.5. Hip Osteoarthritis
5.6. Hand Osteoarthritis
5.7. Others

Chapter 6. Osteoarthritis Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Osteoarthritis Therapeutics Market Movement Analysis
6.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral Route
6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.1.1. Hyaluronic Acid Injections
6.4.1.2. Corticosteroid Injections
6.4.1.3. Platelet-rich Plasma (PRP) Injections
6.4.1.4. Placental Tissue Matrix (PTM) Injections
6.4.1.5. Acetylsalicylic Acid (ASA) Injections
6.4.1.6. Others
6.5. Topical Route
6.6. Oral Route

Chapter 7. Osteoarthritis Therapeutics Market: Sales Channel Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Osteoarthritis Therapeutics Market Movement Analysis
7.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
7.4. Prescription Drugs
7.5. Over-the-Counter Drugs

Chapter 8. Osteoarthritis Therapeutics Market: End-use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Osteoarthritis Therapeutics Market Movement Analysis
8.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by End Use 2018 to 2030 (USD Million)
8.4. Hospital Pharmacies
8.5. Retail Pharmacies
8.6. Others

Chapter 9. Osteoarthritis Therapeutics Market: Regional Estimates & Trend Analysis by
9.1. Regional Market Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape

  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Zimmer Biomet
  • Novartis
  • Anika Therapeutics
  • Assertio Therapeutics
  • Bioventus
  • Ferring Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/g5bb4f

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Osteoarthritis Therapeutics Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

HII’s Ingalls Shipbuilding Launches Guided Missile Destroyer George M. Neal (DDG 131)

Yuki Brings Real-Time Cost Optimization to BigQuery

CrownTV Powers Digital Signage Experience at Victoria’s Secret Fifth Avenue Flagship

LGI Homes Introduces Eldorado, Its Largest Seattle-Area Community to Date

Kansas WorkforceONE Expands Career Exploration Across the State with zSpace AR/VR Laptops

Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio

MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio

State Employees’ Credit Union Helps North Carolinians Build Financial Skills Through Free Education Events

Canon Announces Hiroto Kato as President and CEO of Canon Canada Inc.

Editors Picks

2 charged in highway shooting that killed Alberta man in ‘senseless crime’

April 1, 2026

HII’s Ingalls Shipbuilding Launches Guided Missile Destroyer George M. Neal (DDG 131)

April 1, 2026

These Raspberry Pi price hikes are no joke

April 1, 2026

Yuki Brings Real-Time Cost Optimization to BigQuery

April 1, 2026

Latest News

CrownTV Powers Digital Signage Experience at Victoria’s Secret Fifth Avenue Flagship

April 1, 2026

LGI Homes Introduces Eldorado, Its Largest Seattle-Area Community to Date

April 1, 2026

U.S. firm being paid ‘minimal’ for Manitoba’s ER doctor hunt: minister

April 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version